ITERATRUM ALKALOIDS are powerful V hypotensive agents with many desirable ( haracteristies,1-3 but the usefulness of the available preparationis has been limited by a narrow dosage range between hypotensive aud emnetic effects. After the physicochemical separation of some of the alkaloids had been accomplished,4 a search for an alkaloid with a wider spread between hypotensive and emetic doses was undertaken. Parenteral studies in dogs demoiistrated that the hypotensive activity of protoveratrine A was slightly greater than that of protoveratrine B, but did not show differing degrees of dissociation of hypotensive from emetic activity.5 A comparison between protoveratrine A and protoveratrine B in man, however, revealed marked differences when the alkaloids were administered orally: protoveratrine A had strong hypotensive activity but a narrow therapeutic dosage range, whereas protoveratrine B required much larger doses to elicit hypotensive effects but had a wider range between hypotemisive and emetic effects.6-8 These differences prompted a comparative study of the responses of hypertensive patients to intravenous administration of the 2 alkaloids.
ITERATRUM ALKALOIDS are powerful V hypotensive agents with many desirable ( haracteristies,1-3 but the usefulness of the available preparationis has been limited by a narrow dosage range between hypotensive aud emnetic effects. After the physicochemical separation of some of the alkaloids had been accomplished,4 a search for an alkaloid with a wider spread between hypotensive and emetic doses was undertaken. Parenteral studies in dogs demoiistrated that the hypotensive activity of protoveratrine A was slightly greater than that of protoveratrine B, but did not show differing degrees of dissociation of hypotensive from emetic activity.5 A comparison between protoveratrine A and protoveratrine B in man, however, revealed marked differences when the alkaloids were administered orally: protoveratrine A had strong hypotensive activity but a narrow therapeutic dosage range, whereas protoveratrine B required much larger doses to elicit hypotensive effects but had a wider range between hypotemisive and emetic effects.6-8 These differences prompted a comparative study of the responses of hypertensive patients to intravenous administration of the 2 alkaloids.
Material and Methods
Comparative bioassays of protoveratrine A and protoveratrine B were obtained in 13 patients who were known to have essential or renal hypertension, sustained despite the oral or intravenous adininistration of placebos. At least 4 different hypotensive doses of eaeh alkaloid were given intravenously to each subject. The largest dose given to each patient was determined by the production of a fall in blood pressure to or less thaii normal or by nausea or vom-liting. Protoveratrine on 81 occasions, protoveratrine B on 109. No more than 1 study was conducted in a given patient on the same day. Each alkaloid was admninistered in a measured period of 2 nminutes. With the patient in the recumbent position, a technician deternmined blood pressure and pulse rate at intervals of a few minutes during periods of at least 20 nminutes before and several hours after adaministration. Blood pressure was measured by the auscultatory technic according to the criteria of the American Heart Association. Mean blood pressure was calculated as the diastolic pressure plus one third of the difference between systolic and diastolic pressures. The mean value of the lowest 2 mean blood pressures obtained within 25 minutes after administration of an alkaloid was taken as the maximal response to the given dose of the alkaloid. These responses were used to construct logarithmie dose-response curves. The occurrence and severity of paresthesias, nausea, and vonmiting were noted. Electrocardiograms were taken during studies of the larger doses and whenever bradyeardia was marked.
Observations of the effects of protoveratrine B intravenously were muade an additional 48 times in 21 other adult hypertensive patients. This information was used with the above to estimate the dose of protoveratrine B required to produce a fall in blood pressure to 150/100 anm. Hg or less. Results Qualitative Similarities Each alkaloid had strong hypotensive and bradyurotiu activity, aild each was capable of inducing nausea or vomiting. The occurrence and magnitude of these effects varied with the amount of alkaloid given (table 1), but the ti;e of onset and durationi of the effects were similar for the 2 alkaloids.
The first effect was the occurrence within several miinutes of paresthesias, sensations of warmth or burning, which were noted sequentially in the throat, chest, perineum, and extremities. Brief sneezing was common. The paresthesias regressed withiii 30 to 60 minutes.
Systolic and diastolic blood pressure began to fall a few minutes after administratioii of the drugs with maximal response within 12 to 23 minutes. Blood pressure was nmaintained at the lower leve&s for 45 to 90 minlutes ( fig. 1 ). Return to colntrol values occurred in approximately 3 hours. Pulse rate usually decreased slightly durilng the hypoteuisive action of both alkaloids.
Marked silnus bradyeardia, however, of less than 48 beats per minute occurred in 5 patients after each alkaloid. At rates of approximately 40 beats per minute, the site of impulse formation varied between the sinoatrial and atrioventricular nodes in the course of consecutive beats or groups of beats for periods of minutes. During the height of the bradyeardia ventricular or supraventrieular premature beats, at times in bigeminal fashion, were occasionally seen. The T waves in leads V4, V\5, and VT6 were transiently inverted in several patients. All of these effects, the sinus bradyeardia, atrioventricular rhythm, premature beats, and T-wave inversions, were immediately reversible by administration of 0.4 to 1.0 mg. of atropine sulfate intravenously, usually without affecting the blood pressure response ( fig. 2 ).
At the height of the paresthesias, approximately 10 minutes after drug administration, a tight sensation in the chest and epigastrium was occasionalvy noted after the larger doses of either alkaloid. This pain forewarned nausea with or without vomiting and hiccoughs. Emetic responses lasted less than a half hour. For a considerable portion of the dose ranges given to 10 subjects, there was a linear relation between hypotensive response and the log dose in each case. These data were used for the estimation of the relative Iiypotensive potencies of the 2 substances (ctable 2, olumins 1 and 2). On a weight basis protoveratrine B was slightly less potent (82 per cent) than protoveratrine A.
A dose produeing nausea was reached in 10 patients with protoveratrine A (table 2, column 3). Vomitinog occurred in 7 of these patients. Nausea 
Cl Cl CO CO Cl .25, and .38 mg., equivalent to 2.9, 4.4, and 4.6 pg per Kg. The vomiting induced by protoveratrine B occurred after doses that produced subnormal blood pressures. Following normotensive doses of protoveratrine A, small increases in dose induced nausea and vomiting, and a diminished blood pressure response ( fig. 3 ). In contrast, in the same patients subnormal blood pressure could be achieved by protoveratrine B without an emetic response. The remarkable reproducibility of the response of an individual to a given dose of intravenous veratrum is also evident in this figure. Protoveratrine B had less emetic activity than protoveratrine A at equipotent hypo-tensive doses. A statistical comparison of the hypotensive and emetic activities of the 2 alkaloids (table 2) was obtained by determination of tolerance ratios in which the largest doses of protoveratrine B given without nausea were compared with the doses of protoveratrine A producing nausea. These ratios were adjusted for the differences in hypotensive potency of the alkaloids. Protoveratrine B was better tolerated than protoveratrine A (p <.001).
Optimal Dose of Protoveratrine B
The doses of protoveratrine B that lowered the blood pressure of 34 hypertensive patients to 150/100 mm. Hg or less are indicated in (1.8 to 3.0 ,ug./Kg) were effective in 28 patients. It is likely that some of these patients required less, but received doses in this range after recognition that such doses were both strongly hypotensive and well tolerated. Interestingly, the patient who required the smallest dose per kilogram was a strikingly obese woman, and the subject requiring the largest dose was a poorly nourished man.
Discussion
Protoveratrine A and protoveratrine B are tetraesters of the alkamine, protoverine. They differ by a single hydroxyl group in one of the acids4 (table 3) .
The hypotensive effect is largely a reflex action, which originates in the heart (Bezold-Jarisch effect), carotid sinus, and lungs.9-The receptors transmit impulses to the vasomotor center by the vagi and carotid sinus nerves. Vasodilatation is the result of changes The emetic action appears to be a reflex effect that originates in or near the nodose ganglion. 22 The veratrum alkaloids do not directly stimnulate the vomiting center nor the chemoreceptor trigger zone. 23 The dissociation between the hypotensive and emetic activities of the tetraesters of veratrum may be ascribed to differences in the accessibility of the receptors or to intrinsic differences in the receptors themselves at the different sites of hypotensive and emetic action. The degree of the dissociation of activities appears to be influenced by the chemical configurations of the alkaloids.
Protoveratrine B had less emetic activity than protoveratrine A at doses causing equivalent hypotensive effects in hypertensive man 95 per cent limit to the lower 95 per cent limit of the hypotensive potency ratios was less than 150 per cent in 9 of 10 cases.
Protoveratrine B has qualities that favor its clinical use intravenously in hypertensive emergencies. Its potent vasodepressor and cardiodecelerator effects, as well as its development of maximal action within minutes, are particularly valuable in acute left ventricular failure and in eclampsia, acute glomerulonephritis, or malignant hypertension with hypertensive encephalopathy. Derivatives of Rauwolfia, administered intramuscularly, have been exeeedingly useful in the management of urgent hypertensive problems, but in instances requiring a quick and strong hypotensive effect protoveratrine B may be preferable. Indeed, the two have Circulation, Volume XXII, December 1960 been used together, protoveratrine B initravenously to achieve control within 10 to 13 minutes, and alkaloids of Rauwolfia intramuscularly to maintain it.
Orally protoveratrine A is the active alkaloid in mixtures of protoveratrines A and B.6-8 Its long-term use is difficult because of a narrow range between hypotensive and emetic doses. Protoveratrine B can be an effective hypotensive agent when adminiistered orally, but large doses have beeni required due to incomplete absorption or inactivation by the gastrointestinal tract or liver. The hypotensive effect of protoveratrine B orally tends to be prolonged; an emetic response has been rare. Mild neuromuscular effects, muscle tightness and muscle weakness, may be induced. 
Figure 4
The total dose of protoveratrine B and the dose in micrograms per kilogram that reduces the blood pressure of 34 hypertensive patients to or below 150/100 mm. Hg. are plotted against the number of patients yielding the response.
The clinical use of tetraesters of veratruni appears to be safe. No deaths or vascular catastrophes have been ascribed to their use. An oral overdose of 75 times the recommended dose of a mnixture of protoveratrines A and B was tolerated.24 Excessive hypotension after parenteral administration is rare and can be overcome by the injection of 25 mg. of ephedrine sulfate intramuscularly or by other vasoconstrictor agents. Intravenous administration of atropine sulfate in doses of 0.4 to 1.0 mg. abolishes undesired vagal effects on heart rate and rhythm, usually without loss of the hypotensive response. [25] [26] [27] The transient T-wave inversions induced by veratrum in the left precordial leads resemble those observed in anxious patients during hyperventilation. 28 29 In both cases the Twave changes can be reversed by vagolytic agents.
Although biologic assay teehnies are uncommonly used in man, fixed hypertension lends itself to their application. The virtues of such technics in human pharmacology have been demonstrated in studies of digitalis glycosides30 and diuretics.3' Comparative bioassays in stable clinical disease states foster the pereeption of clinically significant differences among drugs that are chemically closely related.
Summary
Comparative studies of intravenously administered protoveratrine A and protoveratrine B in hypertensive maan indicate that the alkaloids have qualitatively similar hypotensive, bradyerotic, and emetic actions, but quantitatively different hypotensive and emetic potency. The relative hypotensive potencies of the two substances were determined by analyses of logarithmic dose-response curves in the same patients. On a weight basis protoveratrine B was slightly less potent than protoveratrine A.
A favorable dissociation between hypotensive and emetic activity was found. Tolerance ratios were determined in which the largest doses of protoveratrine B given without nausea were compared with the doses of protoveratrine A producing nausea. These ratios were adjusted for the differences in hypotensive potency of the alkaloids. Protoveratrine B was better tolerated than protoveratrine A (p <.001). Indeed, protoveratrine B had little emetic activity when given intravenously in doses producing normotension. Protoveratrine B appears to have properties that warrant its preferential selection for parenteral administration. Its effective dosage range has been studied.
The strong hypotensive activity of intravenously administered protoveratrine B, its development of maximal action within minutes, and its pulse-slowing effect favor its use in those hypertensive states in which almost immediate lowering of the blood pressure is indicated.
Fixed hypertension lends itself to the application of biological assay technics. The use of such technics in human pharmacology fosters the perception of clinically significant differences among drugs that are chemically closely related. Acknowledgment Un dissociation favorabile inter le activitate hypotensive e le activitate emetic esseva constatate. Proportiones de tolerantia esseva determinate in que le doses maximal de protoveratrina administrate sin subsequente nausea esseva comparate con le doses de protoveratrina A que produceva tal nausea. Iste proportiones esseva adjustate pro le differentias in le potentia hypoteinsive del duo alealoides. Protoveratrina B esseva melio tolerate que protoveratrina A (p minus que 0,001). IDe facto, protoveratrina B habeva paue activitate emetic quando illo esseva administrate intravenosemente in doses producente normotension. Protoveratrina B pare haber proprietates que justifica su selection preferential pro administrationes parenteral. Su gamma de dosage efficace esseva studiate.
Le forte activitate hypotensive de protoveratrina B in administration intravenose, le facto que illo disveloppa su effecto maximal intra alicun minutas, e su effecto relentatori super le pulso es rationes pro recommendar su uso in le statos de hypertension in le quales un reduction quasi immediate del tension de sanguine es indicate.
Hypertension fixe se presta al application de technicas de essayage biologic. Le uso de tal technicas in le pharmacologia human promove le perception de clinicamente significative differentias inter drogas que es chimicamente affin.
